| Joseph Law Orloski, MD | |
|
250 S 21st St, Easton, PA 18042-3851 | |
| (866) 785-8535 | |
| Not Available |
| Full Name | Joseph Law Orloski |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 17 Years |
| Location | 250 S 21st St, Easton, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083815906 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | ME106288 (Florida) | Secondary |
| 207P00000X | Emergency Medicine | MD453671 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Hospital - Easton Campus | Easton, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Luke's Physician Group Inc | 6709798333 | 1739 |
News Archive
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.
Most adverse events that lead patients to discontinue antiplatelet drugs are not rated as serious by clinical trial criteria, shows analysis of the PEGASUS-TIMI 54 trial.
Kit Check, the leader in hospital pharmacy kit processing and medication tracking software, today announced that the United States Patent and Trademark Office has issued the company two meaningful patents, with two additional patents set to issue on June 16, 2015. These awards represent a robust portfolio of intellectual property (IP) related to the Kit Check product.
When a large combat unit, widely dispersed in dense jungle, goes to battle, no single soldier knows precisely how his actions are affecting the unit's success or failure. But in modern armies, every soldier is connected via an audio link that can instantly receive broadcasts - reporting both positive and negative surprises - based on new intelligence. The real-time broadcasts enable dispersed troops to learn from these reports and can be critical since no solider has an overview of the entire unit's situation.
The Washington Post examines global efforts to eradicate Guinea worm disease, writing, "The parasitic infection which has sickened millions, mostly in Asia and Africa, is on the verge of being done in not by sophisticated medicine but by aggressive public health efforts in some of the poorest and most remote parts of the world."
› Verified 9 days ago
| Entity Name | St Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700984622 PECOS PAC ID: 6709798333 Enrollment ID: O20040226000062 |
News Archive
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.
Most adverse events that lead patients to discontinue antiplatelet drugs are not rated as serious by clinical trial criteria, shows analysis of the PEGASUS-TIMI 54 trial.
Kit Check, the leader in hospital pharmacy kit processing and medication tracking software, today announced that the United States Patent and Trademark Office has issued the company two meaningful patents, with two additional patents set to issue on June 16, 2015. These awards represent a robust portfolio of intellectual property (IP) related to the Kit Check product.
When a large combat unit, widely dispersed in dense jungle, goes to battle, no single soldier knows precisely how his actions are affecting the unit's success or failure. But in modern armies, every soldier is connected via an audio link that can instantly receive broadcasts - reporting both positive and negative surprises - based on new intelligence. The real-time broadcasts enable dispersed troops to learn from these reports and can be critical since no solider has an overview of the entire unit's situation.
The Washington Post examines global efforts to eradicate Guinea worm disease, writing, "The parasitic infection which has sickened millions, mostly in Asia and Africa, is on the verge of being done in not by sophisticated medicine but by aggressive public health efforts in some of the poorest and most remote parts of the world."
› Verified 9 days ago
| Entity Name | The Good Samaritan Hospital Of Lebanon, Pennsylvania |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730754284 PECOS PAC ID: 5597751206 Enrollment ID: O20040420001427 |
News Archive
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.
Most adverse events that lead patients to discontinue antiplatelet drugs are not rated as serious by clinical trial criteria, shows analysis of the PEGASUS-TIMI 54 trial.
Kit Check, the leader in hospital pharmacy kit processing and medication tracking software, today announced that the United States Patent and Trademark Office has issued the company two meaningful patents, with two additional patents set to issue on June 16, 2015. These awards represent a robust portfolio of intellectual property (IP) related to the Kit Check product.
When a large combat unit, widely dispersed in dense jungle, goes to battle, no single soldier knows precisely how his actions are affecting the unit's success or failure. But in modern armies, every soldier is connected via an audio link that can instantly receive broadcasts - reporting both positive and negative surprises - based on new intelligence. The real-time broadcasts enable dispersed troops to learn from these reports and can be critical since no solider has an overview of the entire unit's situation.
The Washington Post examines global efforts to eradicate Guinea worm disease, writing, "The parasitic infection which has sickened millions, mostly in Asia and Africa, is on the verge of being done in not by sophisticated medicine but by aggressive public health efforts in some of the poorest and most remote parts of the world."
› Verified 9 days ago
| Entity Name | Emergency Physician Associates Of Pennsylvania Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619990900 PECOS PAC ID: 5597663252 Enrollment ID: O20040913000755 |
News Archive
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.
Most adverse events that lead patients to discontinue antiplatelet drugs are not rated as serious by clinical trial criteria, shows analysis of the PEGASUS-TIMI 54 trial.
Kit Check, the leader in hospital pharmacy kit processing and medication tracking software, today announced that the United States Patent and Trademark Office has issued the company two meaningful patents, with two additional patents set to issue on June 16, 2015. These awards represent a robust portfolio of intellectual property (IP) related to the Kit Check product.
When a large combat unit, widely dispersed in dense jungle, goes to battle, no single soldier knows precisely how his actions are affecting the unit's success or failure. But in modern armies, every soldier is connected via an audio link that can instantly receive broadcasts - reporting both positive and negative surprises - based on new intelligence. The real-time broadcasts enable dispersed troops to learn from these reports and can be critical since no solider has an overview of the entire unit's situation.
The Washington Post examines global efforts to eradicate Guinea worm disease, writing, "The parasitic infection which has sickened millions, mostly in Asia and Africa, is on the verge of being done in not by sophisticated medicine but by aggressive public health efforts in some of the poorest and most remote parts of the world."
› Verified 9 days ago
| Entity Name | Dubois Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992802391 PECOS PAC ID: 5890689715 Enrollment ID: O20050411000464 |
News Archive
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.
Most adverse events that lead patients to discontinue antiplatelet drugs are not rated as serious by clinical trial criteria, shows analysis of the PEGASUS-TIMI 54 trial.
Kit Check, the leader in hospital pharmacy kit processing and medication tracking software, today announced that the United States Patent and Trademark Office has issued the company two meaningful patents, with two additional patents set to issue on June 16, 2015. These awards represent a robust portfolio of intellectual property (IP) related to the Kit Check product.
When a large combat unit, widely dispersed in dense jungle, goes to battle, no single soldier knows precisely how his actions are affecting the unit's success or failure. But in modern armies, every soldier is connected via an audio link that can instantly receive broadcasts - reporting both positive and negative surprises - based on new intelligence. The real-time broadcasts enable dispersed troops to learn from these reports and can be critical since no solider has an overview of the entire unit's situation.
The Washington Post examines global efforts to eradicate Guinea worm disease, writing, "The parasitic infection which has sickened millions, mostly in Asia and Africa, is on the verge of being done in not by sophisticated medicine but by aggressive public health efforts in some of the poorest and most remote parts of the world."
› Verified 9 days ago
| Entity Name | Emergency Care Services Of Pennsylvania Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114955010 PECOS PAC ID: 1759301799 Enrollment ID: O20051206000046 |
News Archive
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.
Most adverse events that lead patients to discontinue antiplatelet drugs are not rated as serious by clinical trial criteria, shows analysis of the PEGASUS-TIMI 54 trial.
Kit Check, the leader in hospital pharmacy kit processing and medication tracking software, today announced that the United States Patent and Trademark Office has issued the company two meaningful patents, with two additional patents set to issue on June 16, 2015. These awards represent a robust portfolio of intellectual property (IP) related to the Kit Check product.
When a large combat unit, widely dispersed in dense jungle, goes to battle, no single soldier knows precisely how his actions are affecting the unit's success or failure. But in modern armies, every soldier is connected via an audio link that can instantly receive broadcasts - reporting both positive and negative surprises - based on new intelligence. The real-time broadcasts enable dispersed troops to learn from these reports and can be critical since no solider has an overview of the entire unit's situation.
The Washington Post examines global efforts to eradicate Guinea worm disease, writing, "The parasitic infection which has sickened millions, mostly in Asia and Africa, is on the verge of being done in not by sophisticated medicine but by aggressive public health efforts in some of the poorest and most remote parts of the world."
› Verified 9 days ago
| Entity Name | Gslpg, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366006702 PECOS PAC ID: 7810226875 Enrollment ID: O20190917001763 |
News Archive
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.
Most adverse events that lead patients to discontinue antiplatelet drugs are not rated as serious by clinical trial criteria, shows analysis of the PEGASUS-TIMI 54 trial.
Kit Check, the leader in hospital pharmacy kit processing and medication tracking software, today announced that the United States Patent and Trademark Office has issued the company two meaningful patents, with two additional patents set to issue on June 16, 2015. These awards represent a robust portfolio of intellectual property (IP) related to the Kit Check product.
When a large combat unit, widely dispersed in dense jungle, goes to battle, no single soldier knows precisely how his actions are affecting the unit's success or failure. But in modern armies, every soldier is connected via an audio link that can instantly receive broadcasts - reporting both positive and negative surprises - based on new intelligence. The real-time broadcasts enable dispersed troops to learn from these reports and can be critical since no solider has an overview of the entire unit's situation.
The Washington Post examines global efforts to eradicate Guinea worm disease, writing, "The parasitic infection which has sickened millions, mostly in Asia and Africa, is on the verge of being done in not by sophisticated medicine but by aggressive public health efforts in some of the poorest and most remote parts of the world."
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joseph Law Orloski, MD 3423 Sturbridge Pl, Allentown, PA 18104-1767 Ph: (610) 295-2048 | Joseph Law Orloski, MD 250 S 21st St, Easton, PA 18042-3851 Ph: (866) 785-8535 |
News Archive
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.
Most adverse events that lead patients to discontinue antiplatelet drugs are not rated as serious by clinical trial criteria, shows analysis of the PEGASUS-TIMI 54 trial.
Kit Check, the leader in hospital pharmacy kit processing and medication tracking software, today announced that the United States Patent and Trademark Office has issued the company two meaningful patents, with two additional patents set to issue on June 16, 2015. These awards represent a robust portfolio of intellectual property (IP) related to the Kit Check product.
When a large combat unit, widely dispersed in dense jungle, goes to battle, no single soldier knows precisely how his actions are affecting the unit's success or failure. But in modern armies, every soldier is connected via an audio link that can instantly receive broadcasts - reporting both positive and negative surprises - based on new intelligence. The real-time broadcasts enable dispersed troops to learn from these reports and can be critical since no solider has an overview of the entire unit's situation.
The Washington Post examines global efforts to eradicate Guinea worm disease, writing, "The parasitic infection which has sickened millions, mostly in Asia and Africa, is on the verge of being done in not by sophisticated medicine but by aggressive public health efforts in some of the poorest and most remote parts of the world."
› Verified 9 days ago
Dr. Dustin William Wells, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1872 St Lukes Blvd, Easton, PA 18045 Phone: 484-526-1000 | |
Michael Omead Ghodsi, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1872 St Lukes Blvd, Easton, PA 18045 Phone: 484-526-1000 | |
Michael Kotil, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1872 St Lukes Blvd, Easton, PA 18045 Phone: 484-526-1000 | |
Aerin Julian Bard, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1872 St Lukes Blvd, Easton, PA 18045 Phone: 484-503-3073 | |
Dr. Amy Renee Raghavan, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 S 21st St, Easton, PA 18042 Phone: 866-785-8537 | |
Chance Kenneth Rohrbaugh, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1872 St Luke's Blvd, Easton, PA 18045 Phone: 484-526-1000 |